Medicus Pharma Ltd. SEC filings MDCXW
Medicus Pharma Ltd. has 343 filings in SEC EDGAR's recent list, going back to Oct 13, 2023. Its latest annual report, Form ARS, was filed on May 4, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Oct 23, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 16, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Agreement ended
|
Sep 14, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 11, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 3, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Material agreement, New debt, Listing notice
|
May 27, 2026 | May 20, 2026 |
| 8-K |
Current report
Material agreement, Listing notice
|
Apr 24, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Mar 6, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Material agreement
|
Dec 30, 2025 | Dec 29, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 8, 2025 | Dec 5, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 1, 2025 | Nov 28, 2025 |
| 8-K |
Current report
Other events
|
Nov 14, 2025 | Nov 14, 2025 |
| 8-K |
Current report
Unregistered share sale
|
Oct 17, 2025 | Oct 16, 2025 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Sep 18, 2025 | Sep 17, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 12, 2025 | Sep 12, 2025 |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale, Officer or director change, Other events
|
Sep 2, 2025 | Aug 29, 2025 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Aug 22, 2025 | Aug 21, 2025 |
| 8-K |
Current report
Other events
|
Aug 4, 2025 | Aug 4, 2025 |
| 8-K |
Current report
Other events
|
Jul 30, 2025 | Jul 29, 2025 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jul 23, 2025 | Jul 22, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 14, 2025 | Jul 14, 2025 |
| 8-K/A | Amended current report | Jul 3, 2025 | Jun 29, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 30, 2025 | Jun 29, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Jun 23, 2025 | Jun 23, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 20, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Auditor change
|
Jun 5, 2025 | Jun 3, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 2, 2025 | May 29, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
May 5, 2025 | May 2, 2025 |
| 8-K |
Current report
Other events
|
Apr 28, 2025 | Apr 26, 2025 |
| 8-K |
Current report
Other events
|
Mar 25, 2025 | Mar 21, 2025 |
| 8-K |
Current report
Other events
|
Mar 20, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Mar 11, 2025 | Mar 6, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Feb 11, 2025 | Feb 10, 2025 |
| 6-K | Current report (foreign issuer) | Dec 26, 2024 | Dec 23, 2024 |
| 6-K | Current report (foreign issuer) | Dec 12, 2024 | Dec 12, 2024 |
| 6-K | Current report (foreign issuer) | Dec 2, 2024 | Dec 2, 2024 |
| 6-K | Current report (foreign issuer) | Nov 25, 2024 | Sep 30, 2024 |
| 6-K | Current report (foreign issuer) | Nov 18, 2024 | Nov 13, 2024 |
| 6-K | Current report (foreign issuer) | Nov 18, 2024 | Nov 13, 2024 |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDCX (Nasdaq), MDCXW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- W. Conshohocken, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1997296
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.